A post-market, parallel group clinical trial of Xeomin (incobotulinumtoxinA) versus Botox Cosmetic (onabotulinumtoxinA) in the treatment of moderate to severe glabellar facial lines.

Trial Profile

A post-market, parallel group clinical trial of Xeomin (incobotulinumtoxinA) versus Botox Cosmetic (onabotulinumtoxinA) in the treatment of moderate to severe glabellar facial lines.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Mar 2016

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Glabellar lines
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Mar 2016 Results presented at the 74th Annual Meeting of the American Academy of Dermatology
    • 02 Nov 2015 Results published in the journal Dermatologic Surgery, according to a Merz Aestherics media release.
    • 23 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top